Announcements Trials

Browse Landscape

Phase

Phase 2 6 Phase 1 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 23 Lung Neoplasms 11 Neoplasm Metastasis 4 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Noonan Syndrome 1 Non-Small Cell Lung Cancer With EGFR Mutation 1 Neoplasms, Squamous Cell 1 Neoplasms by Site 1 Mesothelioma 1 Lung Diseases 1 Inhibition, Psychological 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Esophageal Squamous Cell Carcinoma 1

Interventions

Temozolomide 26 Bevacizumab 14 Radiosurgery 12 Radiotherapy 9 pembrolizumab 8 Carboplatin 8 Trastuzumab 6 temsirolimus 5 Sirolimus 5 Erlotinib Hydrochloride 5 abemaciclib 4 Paclitaxel 4 Irinotecan 4 Capecitabine 4 tipifarnib 3 Sorafenib 3 Radiation 3 Mental Status and Dementia Tests 3 Ipilimumab 3 Everolimus 3 Aminolevulinic Acid 3 130-nm albumin-bound paclitaxel 3 tucatinib 2 pertuzumab 2 fludarabine 2 durvalumab 2 alovudine 2 alectinib 2 Vorinostat 2 Surgical Procedures, Operative 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Brain Neoplasms × osimertinib × Clear all

NCT07206498 2025-11-28

WAYWIN103

Wayshine Biopharm, Inc.

Phase 1/2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡